New and emerging treatments for headache.

Expert Rev Neurother

Published: November 2012

Download full-text PDF

Source
http://dx.doi.org/10.1586/ern.12.117DOI Listing

Publication Analysis

Top Keywords

emerging treatments
4
treatments headache
4
emerging
1
headache
1

Similar Publications

Background: Previous studies have shown that valvular heart disease (VHD) is closely related to the development of heart-related disease (HRD). However, the current research for the relationship between VHD and HRD is complex and poorly targeted. Meanwhile, these studies lack the support of bibliometric analysis results.

View Article and Find Full Text PDF

Laetrile, known as vitamin B17, is often used interchangeably with amygdalin. Laetrile is a semi-synthesis product of amygdalin, whereas amygdalin is a naturally occurring substance in many plants. Both compounds have a nitrile functional group that, when activated by the intestinal enzyme β-glucosidases, releases hydrogen cyanide.

View Article and Find Full Text PDF

Understanding hepcidin for iron management in pregnancy.

Transfus Med

January 2025

SUWON (Surgery, Oncology and Womens), Department of Haematology, University of Oxford, Oxford, UK.

Iron deficiency anaemia (IDA) poses a significant health challenge during pregnancy, affecting up to 30% of pregnant women in the UK. It has been linked to poor health outcomes for the mother, foetus, and the infant. Despite its prevalence and impact, current diagnostic and therapeutic approaches are limited.

View Article and Find Full Text PDF

Introduction: Bruton's tyrosine kinase (BTK) is a cytoplasmic signaling protein expressed across a variety of immune cells, terminally differentiated plasma cells, and natural killer cells. Due to the signal potential and targetable nature of BTK, the use of BTK inhibitors (BTKis) has been proposed for the management of several diseases. Currently, the use of BTKis is under investigations for several dermatological conditions such as pemphigus, systemic lupus erythematosus, hidradenitis suppurativa, atopic dermatitis, and chronic spontaneous urticaria (CSU).

View Article and Find Full Text PDF

Introduction: Intranasal (IN) deferoxamine (DFO) has emerged over the past decade as a promising therapeutic in preclinical experiments across neurodegenerative and neurovascular diseases. As an antioxidant iron chelator, its mechanisms are multimodal, involving the binding of brain iron and the consequent engagement of several pathways to counter pathogenesis across multiple diseases. We and other research groups have shown that IN DFO rescues cognitive impairment in several rodent models of Alzheimer Disease (AD).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!